We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
- Biochemistry
-
1. New-to-nature biocompatible lossen rearrangement in E. coli for industry use- Prof. Stephen Wallace
-
2. De novo designed proteins: a breakthrough in snakebite treatment
- Dr. Susana Vazquez Torres
- Cancer/Oncology
-
3. Y chromosome in cancer- Prof. Dan Theodorescu
-
8. From lab to clinic: bridging cancer genetics and public health
- Prof. Clare Turnbull
-
9. Engineered yeast: a breakthrough in targeted cancer therapies
- Prof. Gautam Dantas
-
11. Cancer vaccines
- Dr. Elias Sayour
-
12. The future of blood tests in cancer treatment
- Dr. Isaac Garcia-Murillas
-
14. Artificial intelligence in precision medicine
- Dr. Michael P. Menden
-
15. How liver X receptor regulates intestinal regeneration and tumor growth
- Dr. Srustidhar Das
- Immunology & Inflammation
-
16. Macrophage-specific therapy and the lung’s mechanosensitive immune response
- Prof. Jahar Bhattacharya
-
17. Role of ETS2 in autoimmune and inflammatory diseases
- Dr. James Lee
-
18. Rheumatic diseases and musculoskeletal pain
- Prof. Anisur Rahman
-
20. Transmembrane domains and the regulation of trogocytosis in T cells
- Dr. Stefano Barbera
- Infectious Diseases/Microbiology
-
22. Lariocidin: a novel antibiotic that disrupts bacterial protein synthesis
- Prof. Gerry Wright
-
23. Kalihinol analog MED6-189: a promising pan-antimalarial candidate
- Prof. Karine Le Roch
-
24. Elite controllers of HIV: from discovery to future therapies
- Prof. Bruce Walker
-
26. Towards developing a universal influenza vaccine
- Prof. Peter Palese
- Methods
-
29. How big data and genomics are personalizing your health
- Prof. Michael Snyder
-
30. The role of preregistration and registered reports in improving research transparency and reproducibility
- Dr. Peter Bonde Ernst-Rasmussen
-
31. Decoding aging: how a proteomic clock predicts mortality and disease across populations
- Dr. M. Austin Argentieri
-
32. MassBank development and future
- Dr. Emma L. Schymanski
-
33. Synthetic whole embryo models and their applications
- Prof. Jacob (Yaqub) Hanna
-
34. Pioneering proteomics: insights on advancements in the science of proteins
- Prof. Ruedi Aebersold
- Neurology/Neuroscience
-
35. Peptide-based eye drops for retinal degeneration: targeting photoreceptor survival with H105A- Dr. S. Patricia Becerra
-
36. Cloaked stem cell grafts: engineering immune-evasive neural transplants for Parkinson's therapy- Prof. Clare L. Parish
-
37. The case of an asymptomatic Alzheimer’s mutation carrier
- Dr. Jorge J. Llibre-Guerra
-
39. Rethinking the amyloid dogma in Alzheimer’s disease
- Prof. George Perry
-
40. Integrated multimodal cell atlas of Alzheimer’s disease
- Dr. Michael Hawrylycz
-
41. How and why neurons die in Alzheimer's disease?
- Prof. Bart De Strooper
-
42. Restoring glucose metabolism: a new approach to reversing cognitive decline in AD
- Prof. Katrin Andreasson
-
43. Advancing ALS genetics through accessible testing
- Dr. Teresa Fecteau
-
44. MicroRNA as a biomarker for early detection of amyotrophic lateral sclerosis
- Dr. Sandra Banack
- Dr. Paul Alan Cox
- Dr. Rachael Dunlop
-
45. Translational research in amyotrophic lateral sclerosis (ALS)
- Prof. Aaron D. Gitler
-
46. Muscarinic acetylcholine receptor modulation in neurological diseases
- Prof. Andrew B. Tobin
- Pharmaceutical Sciences
-
47. Complex in vitro models and the future of drug safety and efficacy assessment
- Dr. Nadine Stokar-Regenscheit
-
48. Unlocking a cryptic pocket: a new approach to safer pain relief
- Prof. Susruta Majumdar
- Dr. Vipin Ashok Rangari
-
49. The state of the art in secondary pharmacology
- Dr. Jean-Pierre Valentin
-
50. The safety, toxicology, and regulation of antibody-drug conjugates
- Dr. Veysel Kayser
-
52. Management of generic drug development: challenges and opportunities
- Mr. Sandeep Patil
-
53. Translational medicine: the risk of failure in delay and how to reduce it
- Prof. Martin Wehling
-
54. Artificial intelligence in guiding cancer treatment decisions
- Prof. Eytan Ruppin
-
55. The regulation of cell therapy
- Prof. Moutih Rafei
-
56. Scale-up challenges in the production of nanomedicines from lab to industry
- Prof. Dr. Oya Tagit
-
57. Challenges and solutions of scaling up
- Dr. Shaukat Ali
-
59. Using real-world insights on drug interactions to inform drug development
- Dr. Amita Datta-Mannan
-
60. Role of marketing authorization holder in drug safety
- Dr. Raphael Elmadjian Pareschi
- Microbiology
-
61. Plastic-degrading enzymes in clinical isolates of Pseudomonas aeruginosa- Prof. Ronan McCarthy
Topics Covered
- Infectious diseases
- Mucosal vaccines
- Norovirus vaccines
- Future vaccine design for aging demographics
- Immunosenescence
- Norovirus G11
- Thermostable oral vaccine platform
Biography
Dr. Becca Flitter is an immunologist and vaccine-development scientist, currently serving as a Director at Vaxart, Inc., where she leads a team focused on oral tablet vaccines. She holds a PhD and MPH in Immunology — she completed her doctoral training at University of Pittsburgh. Over two decades, Dr. Flitter has developed deep expertise in mucosal immunology, host-pathogen interactions, and vaccine research. Among her recent achievements: she led the development of an oral norovirus vaccine tablet that, in a 2025 phase 1b clinical trial, was shown to be safe and capable of eliciting robust mucosal immunity (serum and mucosal IgA, mucosal homing B/T cell responses) in older adults. Her work, and that of her team at Vaxart, aims to deliver temperature-stable, needle-free vaccines, which could significantly improve accessibility and ease of immunization worldwide.
Links
Series:
Categories:
Therapeutic Areas:
External Links
Talk Citation
Flitter, B. (2026, January 28). Fighting norovirus with a pill: new vaccine shows strong immune response [Audio file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 22, 2026, from https://doi.org/10.69645/YWBP1886.Export Citation (RIS)
Publication History
- Published on January 28, 2026
Financial Disclosures
- Dr. Becca Flitter has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.